Our outstanding researchers are dedicated to translating cutting-edge medical revelations from bench to bedside in renal diseases and other metabolic disorders.
The Center for Renal Precision medicine consists of both bench research projects and clinical trials that aim to provide insight for novel treatments of kidney diseases. Click the link above to learn about our previous and current research studies.
NIRVANA is the first nIH funded investigator-initiated multi-center interventional clinical trial and UT Health San Antonio is the coordinating site. Patients enrolled with evidence of AKI and recent COVID-19 infection will be randomized in this placebo controlled trial to treatments to boost mitochondrial function. Overall PI: Kumar Sharma, Co-PI: Brian Reeves, Tareq Nassar. Study Project Leader: Subrata Debnath.
NIRVANA is a pilot, double-blind, placebo-controlled, multicenter, interventional clinical trial with oral nicotinamide riboside (NR) 500 mg (versus placebo) twice daily for a total of 10 days in hospitalized participants with COVID-19. The purpose of this study is to determine the effect of NR on whole blood NAD+ levels and evaluate the safety of NR in hospitalized patients with COVID-19 and AKI during a 10-day intervention period. The potential benefit for patients enrolled in this study would be less kidney injury and preservation of kidney function to reduce the degree of chronic kidney disease in patients with COVID-19.
There are no events at this time. Please check back later.